Effect of pentobarbitone sodium and bromocriptine on follicular oestradiol production in the rat.
Injection of an ovulation-blocking dose of pentobarbitone sodium given in the early afternoon of pro-oestrus in rats decreased follicular oestradiol production in vitro the next day (2.42 +/- 0.11 ng/4 h/follicle in pro-oestrous rats, 0.49 +/- 0.04 ng/4 h/follicle in pentobarbitone-treated rats). Pentobarbitone, given 1 day earlier (at dioestrus II), prevented the increase in oestradiol production that normally occurs between di-oestrus II and pro-oestrus. Injection of a subovulatory amount of hCG (0.5 i.u.) given after pentobarbitone injection inhibited the decrease in follicular oestradiol production induced by pentobarbitone. The pentobarbitone-induced decrease in oestradiol production was also prevented by bromocriptine (1 mg) given at di-oestrus II (15:00 h) and pro-oestrus (09:00 h). Bromocriptine is an effective inhibitor of prolactin secretion and this suggests therefore that the decrease in follicular oestradiol production after pentobarbitone is due to the preovulatory surge of prolactin. However, pretreatment with bromocriptine also inhibited the effect of pentobarbitone on oestradiol production when pentobarbitone was given at di-oestrus II. Moreover, when ergocornine (another inhibitor of prolactin secretion) was used instead of pentobarbitone to block ovulation, follicular oestradiol production was also decreased the next day. In contrast to bromocriptine, ergocornine was not able to prevent the pentobarbitone-induced decrease in follicular oestradiol production. These results indicate that the decrease in follicular oestradiol production after pentobarbitone injection is due to inhibition of the serum concentrations of LH rather than the preovulatory surge of prolactin. How bromocriptine (but not ergocornine) prevents the pentobarbitone-induced decrease in oestradiol production is not clear.
Uilenbroek
J T
JT
Department of Endocrinology, Growth and Reproduction, Faculty of Medicine, Erasmus University, Rotterdam, The Netherlands.
D000818:Animals; D001971:Bromocriptine / Q000494:pharmacology*; D006063:Chorionic Gonadotropin / Q000494:pharmacology; D004031:Diestrus; D004873:Ergolines / Q000494:pharmacology; D004958:Estradiol / Q000096:biosynthesis*; D005260:Female; D007986:Luteinizing Hormone / Q000097:blood; D006080:Ovarian Follicle / Q000378:metabolism*; D010424:Pentobarbital / Q000494:pharmacology*; D011359:Proestrus; D011388:Prolactin / Q000097:blood; D051381:Rats; D011919:Rats, Inbred Strains
D006063:Chorionic Gonadotropin; D004873:Ergolines; D001971:Bromocriptine; D004958:Estradiol; C100271:ergocornine; D011388:Prolactin; D007986:Luteinizing Hormone; D010424:Pentobarbital